Arcutis Biotherapeutics, Inc.

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $0 $0 $0 $3.7m
$59.6m +1517.09%
$196.5m +229.74%
$376.1m +91.34%
$464.0m +23.38%
Revenue from Contract with Customer, Including Assessed Tax $0 $0 $3.7m $59.6m $166.5m $372.1m
Other revenue $0 $30.4m $30.0m $4.0m
Cost of Revenue $36.5m
$0 -100.00%
$0 $754k
$5.0m +561.41%
$19.1m +283.56%
$36.7m +91.84%
$41.1m +11.99%
Cost of sales $36.5m
$0 -100.00%
$0 $754k
$5.0m +561.41%
$19.1m +283.56%
$36.7m +91.84%
$41.1m +11.99%
Gross Profit (Calculated) (derived) ($36.5m)
$0 +100.00%
$0 $2.9m
$54.6m +1762.86%
$177.4m +224.82%
$339.4m +91.29%
Research and Development Expense $17.9m $36.5m $115.3m $145.6m $182.4m $110.6m $76.4m $77.1m $91.0m
General and Administrative Expense $6.6m $21.3m $61.0m $122.1m $185.1m $229.4m $274.6m
Amortization of Intangible Assets $312k $750k $2.0m $4.7m
Operating Lease, Expense $151k $602k $686k $716k
Operating Expenses $19.7m $43.1m $136.6m $206.5m $305.3m $300.7m $324.9m $388.3m $388.6m
Loss from operations ($19.7m)
($43.1m) -118.56%
($136.6m) -216.81%
($206.5m) -51.14%
($301.6m) -46.05%
($241.1m) +20.07%
($128.4m) +46.75%
($12.2m) +90.48%
Operating Income (Loss) ($19.7m)
($43.1m) -118.56%
($136.6m) -216.81%
($206.5m) -51.14%
($301.6m) -46.05%
($241.1m) +20.07%
($128.4m) +46.75%
($12.2m) +90.48%
$34.3m +380.14%
Interest Income, Other $12.5m $16.1m $8.9m $8.8m
Other Nonoperating Income (Expense) $967k $173k $5.8m $11.8m $16.2m $443k
Other income (expense), net $967k $173k $5.8m $11.8m $16.2m $443k $53k
Interest Expense (non-operating) $0 $0 $15.7m $29.7m $27.2m $12.1m $13.8m
Income (Loss) from Continuing Operations before Income Taxes, Domestic $206.4m $311.5m ($255.7m) ($130.4m) ($8.2m) $29.3m
Loss before income taxes ($206.4m) ($311.5m) ($259.0m) ($139.4m) ($15.0m)
Provision for income taxes $0 $0 $0 $0 $3.1m $647k $1.2m
Current Income Tax Expense (Benefit) $3.1m $799k $1.1m $779k
Net loss ($19.3m) ($42.0m) ($135.7m) ($206.4m) ($311.5m) ($262.1m) ($140.0m) ($16.1m)
Net Income (Loss) Attributable to Parent ($19.3m)
($42.0m) -118.10%
($135.7m) -223.07%
($206.4m) -52.09%
($311.5m) -50.93%
($262.1m) +15.83%
($140.0m) +46.58%
($16.1m) +88.47%
$28.5m +276.69%
Earnings Per Share, Basic ($4.18) ($5.66) ($3.78) ($1.16) ($0.13) $0.22
Earnings Per Share, Diluted ($4.18) ($5.66) ($3.78) ($1.16) ($0.13) $0.22
Weighted Average Number of Shares Outstanding, Basic 49.4m 55.0m 69.3m 121.0m 127.2m 128.9m
Weighted Average Number of Shares Outstanding, Diluted 49.4m 55.0m 69.3m 121.0m 127.2m 131.9m
Additional Financial Items
Costs and Expenses $300.7m $324.9m $388.3m
Income (Loss) Attributable to Parent, before Tax ($259.0m) ($139.4m) ($15.0m)
Unrealized gain on marketable securities $0 ($1k) ($1k) ($253k) ($831k) $1.2m $219k ($206k)
Foreign currency translation adjustment $0 $0 ($96k) ($230k) $169k
Comprehensive loss ($19.3m) ($42.0m) ($135.7m) ($206.6m) ($312.3m) ($261.1m) ($140.1m) ($16.2m)
Total other comprehensive income (loss) ($253k) ($831k) $1.1m ($11k) ($37k)